chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Asthenia, Back pain, Chest discomfort, Chills, Dyspnoea
Clinical narrative: blood clots forming in my lungs; Fatigue; Coughing; Pulmonary Embolism; Lower back pain; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; This is a spontaneous report from a contactable consumer (patient). A 35-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 26Apr2021 11:15 (Lot Number: ER8729, at age of 35 years old) as single dose for COVID-19 immunisation. Medical history included mild asthma, mild allergy to latex. Concomitant medications included albuterol [salbutamol] taken for asthma; cyanocobalamin (VITAMIN B12); vitamin d. The patient previously received first dose of BNT162B2 on 05Apr2021 for COVID-19 immunisation (Brand=Pfizer ER8736; time: 11:15 AM; location: Left arm; Facility type: Hospital). The patient experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine in Apr2021. Trouble breathing too. Initially diagnosed with Pneumonia a week later on 03May2021 by chest X-ray. Symptoms did not resolve after antibiotics and fatigue and breathing troubles got worse in May2021. Coughing also became a symptom in May2021. Also, lung pain intensified several weeks later along with chest pain. On 30May2021 was rushed to ER and diagnosed with bilateral Pulmonary Embolism via CT contrast scan. It appeared patient never had Pneumonia, but instead blot clots forming in his lungs on unknown date. It was also reported adverse event start date: 06Apr2021; Adverse event start time: 04:45 PM. Adverse events resulted: in [Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event), Disability or permanent damage] Hospitalization: 1 day. The patient underwent additional lab tests and procedures: COVID test post vaccination: Nasal Swab PCR on 03May2021 result: Negative; Blood test IGG IGM on 01Jun2021 result: Positive. The patient received treatment as Lovenox injections and blood thinner prescription. The outcome of events was recovering.
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Muscle tightness, Musculoskeletal chest pain, Musculoskeletal stiffness, Pain, Pyrexia
Clinical narrative: blood clots forming in my lungs; Fatigue; Coughing; Pulmonary Embolism; Lower back pain; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; This is a spontaneous report from a contactable consumer (patient). A 35-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 26Apr2021 11:15 (Lot Number: ER8729, at age of 35 years old) as single dose for COVID-19 immunisation. Medical history included mild asthma, mild allergy to latex. Concomitant medications included albuterol [salbutamol] taken for asthma; cyanocobalamin (VITAMIN B12); vitamin d. The patient previously received first dose of BNT162B2 on 05Apr2021 for COVID-19 immunisation (Brand=Pfizer ER8736; time: 11:15 AM; location: Left arm; Facility type: Hospital). The patient experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine in Apr2021. Trouble breathing too. Initially diagnosed with Pneumonia a week later on 03May2021 by chest X-ray. Symptoms did not resolve after antibiotics and fatigue and breathing troubles got worse in May2021. Coughing also became a symptom in May2021. Also, lung pain intensified several weeks later along with chest pain. On 30May2021 was rushed to ER and diagnosed with bilateral Pulmonary Embolism via CT contrast scan. It appeared patient never had Pneumonia, but instead blot clots forming in his lungs on unknown date. It was also reported adverse event start date: 06Apr2021; Adverse event start time: 04:45 PM. Adverse events resulted: in [Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event), Disability or permanent damage] Hospitalization: 1 day. The patient underwent additional lab tests and procedures: COVID test post vaccination: Nasal Swab PCR on 03May2021 result: Negative; Blood test IGG IGM on 01Jun2021 result: Positive. The patient received treatment as Lovenox injections and blood thinner prescription. The outcome of events was recovering.
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Sleep disorder
Clinical narrative: blood clots forming in my lungs; Fatigue; Coughing; Pulmonary Embolism; Lower back pain; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; This is a spontaneous report from a contactable consumer (patient). A 35-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 26Apr2021 11:15 (Lot Number: ER8729, at age of 35 years old) as single dose for COVID-19 immunisation. Medical history included mild asthma, mild allergy to latex. Concomitant medications included albuterol [salbutamol] taken for asthma; cyanocobalamin (VITAMIN B12); vitamin d. The patient previously received first dose of BNT162B2 on 05Apr2021 for COVID-19 immunisation (Brand=Pfizer ER8736; time: 11:15 AM; location: Left arm; Facility type: Hospital). The patient experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine in Apr2021. Trouble breathing too. Initially diagnosed with Pneumonia a week later on 03May2021 by chest X-ray. Symptoms did not resolve after antibiotics and fatigue and breathing troubles got worse in May2021. Coughing also became a symptom in May2021. Also, lung pain intensified several weeks later along with chest pain. On 30May2021 was rushed to ER and diagnosed with bilateral Pulmonary Embolism via CT contrast scan. It appeared patient never had Pneumonia, but instead blot clots forming in his lungs on unknown date. It was also reported adverse event start date: 06Apr2021; Adverse event start time: 04:45 PM. Adverse events resulted: in [Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event), Disability or permanent damage] Hospitalization: 1 day. The patient underwent additional lab tests and procedures: COVID test post vaccination: Nasal Swab PCR on 03May2021 result: Negative; Blood test IGG IGM on 01Jun2021 result: Positive. The patient received treatment as Lovenox injections and blood thinner prescription. The outcome of events was recovering.
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Back pain, Blood immunoglobulin G, Blood immunoglobulin M, Chest X-ray, Chest discomfort
Clinical narrative: blood clots forming in my lungs; Fatigue; Coughing; Pulmonary Embolism; Lower back pain; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; This is a spontaneous report from a contactable consumer (patient). A 35-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 26Apr2021 11:15 (Lot Number: ER8729, at age of 35 years old) as single dose for COVID-19 immunisation. Medical history included mild asthma, mild allergy to latex. Concomitant medications included albuterol [salbutamol] taken for asthma; cyanocobalamin (VITAMIN B12); vitamin d. The patient previously received first dose of BNT162B2 on 05Apr2021 for COVID-19 immunisation (Brand=Pfizer ER8736; time: 11:15 AM; location: Left arm; Facility type: Hospital). The patient experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine in Apr2021. Trouble breathing too. Initially diagnosed with Pneumonia a week later on 03May2021 by chest X-ray. Symptoms did not resolve after antibiotics and fatigue and breathing troubles got worse in May2021. Coughing also became a symptom in May2021. Also, lung pain intensified several weeks later along with chest pain. On 30May2021 was rushed to ER and diagnosed with bilateral Pulmonary Embolism via CT contrast scan. It appeared patient never had Pneumonia, but instead blot clots forming in his lungs on unknown date. It was also reported adverse event start date: 06Apr2021; Adverse event start time: 04:45 PM. Adverse events resulted: in [Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event), Disability or permanent damage] Hospitalization: 1 day. The patient underwent additional lab tests and procedures: COVID test post vaccination: Nasal Swab PCR on 03May2021 result: Negative; Blood test IGG IGM on 01Jun2021 result: Positive. The patient received treatment as Lovenox injections and blood thinner prescription. The outcome of events was recovering.
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Chest pain, Computerised tomogram, Cough, Dyspnoea, Fatigue
Clinical narrative: blood clots forming in my lungs; Fatigue; Coughing; Pulmonary Embolism; Lower back pain; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; This is a spontaneous report from a contactable consumer (patient). A 35-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 26Apr2021 11:15 (Lot Number: ER8729, at age of 35 years old) as single dose for COVID-19 immunisation. Medical history included mild asthma, mild allergy to latex. Concomitant medications included albuterol [salbutamol] taken for asthma; cyanocobalamin (VITAMIN B12); vitamin d. The patient previously received first dose of BNT162B2 on 05Apr2021 for COVID-19 immunisation (Brand=Pfizer ER8736; time: 11:15 AM; location: Left arm; Facility type: Hospital). The patient experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine in Apr2021. Trouble breathing too. Initially diagnosed with Pneumonia a week later on 03May2021 by chest X-ray. Symptoms did not resolve after antibiotics and fatigue and breathing troubles got worse in May2021. Coughing also became a symptom in May2021. Also, lung pain intensified several weeks later along with chest pain. On 30May2021 was rushed to ER and diagnosed with bilateral Pulmonary Embolism via CT contrast scan. It appeared patient never had Pneumonia, but instead blot clots forming in his lungs on unknown date. It was also reported adverse event start date: 06Apr2021; Adverse event start time: 04:45 PM. Adverse events resulted: in [Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event), Disability or permanent damage] Hospitalization: 1 day. The patient underwent additional lab tests and procedures: COVID test post vaccination: Nasal Swab PCR on 03May2021 result: Negative; Blood test IGG IGM on 01Jun2021 result: Positive. The patient received treatment as Lovenox injections and blood thinner prescription. The outcome of events was recovering.
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Pulmonary embolism, Pulmonary thrombosis, SARS-CoV-2 test
Clinical narrative: blood clots forming in my lungs; Fatigue; Coughing; Pulmonary Embolism; Lower back pain; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; This is a spontaneous report from a contactable consumer (patient). A 35-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 26Apr2021 11:15 (Lot Number: ER8729, at age of 35 years old) as single dose for COVID-19 immunisation. Medical history included mild asthma, mild allergy to latex. Concomitant medications included albuterol [salbutamol] taken for asthma; cyanocobalamin (VITAMIN B12); vitamin d. The patient previously received first dose of BNT162B2 on 05Apr2021 for COVID-19 immunisation (Brand=Pfizer ER8736; time: 11:15 AM; location: Left arm; Facility type: Hospital). The patient experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine in Apr2021. Trouble breathing too. Initially diagnosed with Pneumonia a week later on 03May2021 by chest X-ray. Symptoms did not resolve after antibiotics and fatigue and breathing troubles got worse in May2021. Coughing also became a symptom in May2021. Also, lung pain intensified several weeks later along with chest pain. On 30May2021 was rushed to ER and diagnosed with bilateral Pulmonary Embolism via CT contrast scan. It appeared patient never had Pneumonia, but instead blot clots forming in his lungs on unknown date. It was also reported adverse event start date: 06Apr2021; Adverse event start time: 04:45 PM. Adverse events resulted: in [Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event), Disability or permanent damage] Hospitalization: 1 day. The patient underwent additional lab tests and procedures: COVID test post vaccination: Nasal Swab PCR on 03May2021 result: Negative; Blood test IGG IGM on 01Jun2021 result: Positive. The patient received treatment as Lovenox injections and blood thinner prescription. The outcome of events was recovering.
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Angiogram pulmonary abnormal, Anticoagulant therapy, Blood test, Chest X-ray abnormal, Chest discomfort
Clinical narrative: blood clots forming in my lungs; Fatigue; Coughing; Pulmonary Embolism; Lower back pain; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; This is a spontaneous report from a contactable consumer (patient). A 35-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 26Apr2021 11:15 (Lot Number: ER8729, at age of 35 years old) as single dose for COVID-19 immunisation. Medical history included mild asthma, mild allergy to latex. Concomitant medications included albuterol [salbutamol] taken for asthma; cyanocobalamin (VITAMIN B12); vitamin d. The patient previously received first dose of BNT162B2 on 05Apr2021 for COVID-19 immunisation (Brand=Pfizer ER8736; time: 11:15 AM; location: Left arm; Facility type: Hospital). The patient experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine in Apr2021. Trouble breathing too. Initially diagnosed with Pneumonia a week later on 03May2021 by chest X-ray. Symptoms did not resolve after antibiotics and fatigue and breathing troubles got worse in May2021. Coughing also became a symptom in May2021. Also, lung pain intensified several weeks later along with chest pain. On 30May2021 was rushed to ER and diagnosed with bilateral Pulmonary Embolism via CT contrast scan. It appeared patient never had Pneumonia, but instead blot clots forming in his lungs on unknown date. It was also reported adverse event start date: 06Apr2021; Adverse event start time: 04:45 PM. Adverse events resulted: in [Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event), Disability or permanent damage] Hospitalization: 1 day. The patient underwent additional lab tests and procedures: COVID test post vaccination: Nasal Swab PCR on 03May2021 result: Negative; Blood test IGG IGM on 01Jun2021 result: Positive. The patient received treatment as Lovenox injections and blood thinner prescription. The outcome of events was recovering.
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Chest pain, Dizziness, Dyspnoea, Echocardiogram, Electrocardiogram
Clinical narrative: blood clots forming in my lungs; Fatigue; Coughing; Pulmonary Embolism; Lower back pain; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; This is a spontaneous report from a contactable consumer (patient). A 35-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 26Apr2021 11:15 (Lot Number: ER8729, at age of 35 years old) as single dose for COVID-19 immunisation. Medical history included mild asthma, mild allergy to latex. Concomitant medications included albuterol [salbutamol] taken for asthma; cyanocobalamin (VITAMIN B12); vitamin d. The patient previously received first dose of BNT162B2 on 05Apr2021 for COVID-19 immunisation (Brand=Pfizer ER8736; time: 11:15 AM; location: Left arm; Facility type: Hospital). The patient experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine in Apr2021. Trouble breathing too. Initially diagnosed with Pneumonia a week later on 03May2021 by chest X-ray. Symptoms did not resolve after antibiotics and fatigue and breathing troubles got worse in May2021. Coughing also became a symptom in May2021. Also, lung pain intensified several weeks later along with chest pain. On 30May2021 was rushed to ER and diagnosed with bilateral Pulmonary Embolism via CT contrast scan. It appeared patient never had Pneumonia, but instead blot clots forming in his lungs on unknown date. It was also reported adverse event start date: 06Apr2021; Adverse event start time: 04:45 PM. Adverse events resulted: in [Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event), Disability or permanent damage] Hospitalization: 1 day. The patient underwent additional lab tests and procedures: COVID test post vaccination: Nasal Swab PCR on 03May2021 result: Negative; Blood test IGG IGM on 01Jun2021 result: Positive. The patient received treatment as Lovenox injections and blood thinner prescription. The outcome of events was recovering.
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Fatigue, Gait disturbance, Haemoptysis, Pneumonia, Pulmonary embolism
Clinical narrative: blood clots forming in my lungs; Fatigue; Coughing; Pulmonary Embolism; Lower back pain; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; This is a spontaneous report from a contactable consumer (patient). A 35-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 26Apr2021 11:15 (Lot Number: ER8729, at age of 35 years old) as single dose for COVID-19 immunisation. Medical history included mild asthma, mild allergy to latex. Concomitant medications included albuterol [salbutamol] taken for asthma; cyanocobalamin (VITAMIN B12); vitamin d. The patient previously received first dose of BNT162B2 on 05Apr2021 for COVID-19 immunisation (Brand=Pfizer ER8736; time: 11:15 AM; location: Left arm; Facility type: Hospital). The patient experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine in Apr2021. Trouble breathing too. Initially diagnosed with Pneumonia a week later on 03May2021 by chest X-ray. Symptoms did not resolve after antibiotics and fatigue and breathing troubles got worse in May2021. Coughing also became a symptom in May2021. Also, lung pain intensified several weeks later along with chest pain. On 30May2021 was rushed to ER and diagnosed with bilateral Pulmonary Embolism via CT contrast scan. It appeared patient never had Pneumonia, but instead blot clots forming in his lungs on unknown date. It was also reported adverse event start date: 06Apr2021; Adverse event start time: 04:45 PM. Adverse events resulted: in [Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event), Disability or permanent damage] Hospitalization: 1 day. The patient underwent additional lab tests and procedures: COVID test post vaccination: Nasal Swab PCR on 03May2021 result: Negative; Blood test IGG IGM on 01Jun2021 result: Positive. The patient received treatment as Lovenox injections and blood thinner prescription. The outcome of events was recovering.
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Pulmonary infarction, Renal function test normal, SARS-CoV-2 test negative, Sleep disorder
Clinical narrative: blood clots forming in my lungs; Fatigue; Coughing; Pulmonary Embolism; Lower back pain; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; Experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine. Trouble breathing too. Initially diagnosed with Pneumonia a week late; This is a spontaneous report from a contactable consumer (patient). A 35-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 26Apr2021 11:15 (Lot Number: ER8729, at age of 35 years old) as single dose for COVID-19 immunisation. Medical history included mild asthma, mild allergy to latex. Concomitant medications included albuterol [salbutamol] taken for asthma; cyanocobalamin (VITAMIN B12); vitamin d. The patient previously received first dose of BNT162B2 on 05Apr2021 for COVID-19 immunisation (Brand=Pfizer ER8736; time: 11:15 AM; location: Left arm; Facility type: Hospital). The patient experienced intense chest/ribcage and Lower back pain and tightness around lungs about 30 hours after 2nd dose of COVID19 vaccine in Apr2021. Trouble breathing too. Initially diagnosed with Pneumonia a week later on 03May2021 by chest X-ray. Symptoms did not resolve after antibiotics and fatigue and breathing troubles got worse in May2021. Coughing also became a symptom in May2021. Also, lung pain intensified several weeks later along with chest pain. On 30May2021 was rushed to ER and diagnosed with bilateral Pulmonary Embolism via CT contrast scan. It appeared patient never had Pneumonia, but instead blot clots forming in his lungs on unknown date. It was also reported adverse event start date: 06Apr2021; Adverse event start time: 04:45 PM. Adverse events resulted: in [Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event), Disability or permanent damage] Hospitalization: 1 day. The patient underwent additional lab tests and procedures: COVID test post vaccination: Nasal Swab PCR on 03May2021 result: Negative; Blood test IGG IGM on 01Jun2021 result: Positive. The patient received treatment as Lovenox injections and blood thinner prescription. The outcome of events was recovering.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Dysphagia, Hypersensitivity, Suffocation feeling
Clinical narrative: anaphylaxis; new allergic reactions to items which was never allergic to before: nuts, sea food, hair color; new allergic reactions to items which was never allergic to before: nuts, sea food, hair color; period on already menopause over one year; This is a spontaneous report from contactable reporting for herself. This 53-year-old non-pregnant female patient received the second single dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 02May2021 at 13:15 (at 53 years of age), in left arm, for immunization. The first dose of BNT162B2 vaccine was administered on an unknown date and she experienced hives. Medical history included COVID, allergy to Aspirin, ibuprofen and MIT/CIT/BIT and menopause. Concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 02May2021 at 14:30 the patient experienced anaphylaxis. A couple of days to weeks later, on an unspecified date in 2021, triggered several new allergic reactions to items which was never allergic to before: nuts, sea food, hair color; also triggered, after 2 weeks of the shot, period on already menopause over one year. At hospital anti-histaminic and anti-inflammatory treatment was administered. The events required Doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. The events were reported serious as life-threatening and medically significant and had not yet resolved. Since the vaccination, the patient had not been tested for COVID-19.  Information on the lot/batch number has been requested.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of events cannot be excluded.  The case will be reassessed if additional information becomes available.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-2021642412 same reporter/patient/product, different dose/event.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Anaphylactic reaction, Food allergy, Postmenopausal haemorrhage
Clinical narrative: anaphylaxis; new allergic reactions to items which was never allergic to before: nuts, sea food, hair color; new allergic reactions to items which was never allergic to before: nuts, sea food, hair color; period on already menopause over one year; This is a spontaneous report from contactable reporting for herself. This 53-year-old non-pregnant female patient received the second single dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 02May2021 at 13:15 (at 53 years of age), in left arm, for immunization. The first dose of BNT162B2 vaccine was administered on an unknown date and she experienced hives. Medical history included COVID, allergy to Aspirin, ibuprofen and MIT/CIT/BIT and menopause. Concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 02May2021 at 14:30 the patient experienced anaphylaxis. A couple of days to weeks later, on an unspecified date in 2021, triggered several new allergic reactions to items which was never allergic to before: nuts, sea food, hair color; also triggered, after 2 weeks of the shot, period on already menopause over one year. At hospital anti-histaminic and anti-inflammatory treatment was administered. The events required Doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. The events were reported serious as life-threatening and medically significant and had not yet resolved. Since the vaccination, the patient had not been tested for COVID-19.  Information on the lot/batch number has been requested.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of events cannot be excluded.  The case will be reassessed if additional information becomes available.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-2021642412 same reporter/patient/product, different dose/event.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Urticaria
Clinical narrative: anaphylaxis; new allergic reactions to items which was never allergic to before: nuts, sea food, hair color; new allergic reactions to items which was never allergic to before: nuts, sea food, hair color; period on already menopause over one year; This is a spontaneous report from contactable reporting for herself. This 53-year-old non-pregnant female patient received the second single dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 02May2021 at 13:15 (at 53 years of age), in left arm, for immunization. The first dose of BNT162B2 vaccine was administered on an unknown date and she experienced hives. Medical history included COVID, allergy to Aspirin, ibuprofen and MIT/CIT/BIT and menopause. Concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 02May2021 at 14:30 the patient experienced anaphylaxis. A couple of days to weeks later, on an unspecified date in 2021, triggered several new allergic reactions to items which was never allergic to before: nuts, sea food, hair color; also triggered, after 2 weeks of the shot, period on already menopause over one year. At hospital anti-histaminic and anti-inflammatory treatment was administered. The events required Doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. The events were reported serious as life-threatening and medically significant and had not yet resolved. Since the vaccination, the patient had not been tested for COVID-19.  Information on the lot/batch number has been requested.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of events cannot be excluded.  The case will be reassessed if additional information becomes available.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-2021642412 same reporter/patient/product, different dose/event.
Age: 39.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tinnitus
Clinical narrative: constant relentless tinnitus in her right ear with accompanying ear pressure; constant relentless tinnitus in her right ear with accompanying ear pressure; anxiety; depression; insomnia; This is a spontaneous from a contactable nurse (patient) report. A 39-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in left arm on 08May2021 09:00 (Lot Number: EP7533, at age of 39-year-old) as single dose for covid-19 immunisation. Medical history included allergy to amoxicillin and allergy to shellfish. The patient's concomitant medications were not reported. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 17Apr2021 09:00 (Lot Number: ER8731, at age of 39-year-old) as single dose for covid-19 immunisation. On 09May2021 at 21:00, 36 hours after her injection she developed constant relentless tinnitus in her right ear with accompanying ear pressure. The event resulted in doctor or other healthcare professional office/clinic visit. Treatment included prednisone 40mgs x 6 days, 20mg x1. She now (on May2021) had anxiety, depression, insomnia and was hopeless that this vaccine had ruined her entire life and had been out of work since. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Purified protein derivative (PPD) was given about 6 weeks prior to vaccine (on Mar2021) and unknown results. The patient was not pregnant. The outcome of the events was not recovered.; Sender's Comments: As there is limited information in the case provided, the causal association between the events(Tinnitus, Ear discomfort , Anxiety, Depression, Insomnia) and the suspect vaccine BNT162B2 cannot be excluded. The case will be reassessed once new information is available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
Age: 39.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Anxiety, Depression, Ear discomfort, Insomnia, Tinnitus
Clinical narrative: constant relentless tinnitus in her right ear with accompanying ear pressure; constant relentless tinnitus in her right ear with accompanying ear pressure; anxiety; depression; insomnia; This is a spontaneous from a contactable nurse (patient) report. A 39-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in left arm on 08May2021 09:00 (Lot Number: EP7533, at age of 39-year-old) as single dose for covid-19 immunisation. Medical history included allergy to amoxicillin and allergy to shellfish. The patient's concomitant medications were not reported. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 17Apr2021 09:00 (Lot Number: ER8731, at age of 39-year-old) as single dose for covid-19 immunisation. On 09May2021 at 21:00, 36 hours after her injection she developed constant relentless tinnitus in her right ear with accompanying ear pressure. The event resulted in doctor or other healthcare professional office/clinic visit. Treatment included prednisone 40mgs x 6 days, 20mg x1. She now (on May2021) had anxiety, depression, insomnia and was hopeless that this vaccine had ruined her entire life and had been out of work since. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Purified protein derivative (PPD) was given about 6 weeks prior to vaccine (on Mar2021) and unknown results. The patient was not pregnant. The outcome of the events was not recovered.; Sender's Comments: As there is limited information in the case provided, the causal association between the events(Tinnitus, Ear discomfort , Anxiety, Depression, Insomnia) and the suspect vaccine BNT162B2 cannot be excluded. The case will be reassessed once new information is available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
Age: 39.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tuberculin test
Clinical narrative: constant relentless tinnitus in her right ear with accompanying ear pressure; constant relentless tinnitus in her right ear with accompanying ear pressure; anxiety; depression; insomnia; This is a spontaneous from a contactable nurse (patient) report. A 39-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in left arm on 08May2021 09:00 (Lot Number: EP7533, at age of 39-year-old) as single dose for covid-19 immunisation. Medical history included allergy to amoxicillin and allergy to shellfish. The patient's concomitant medications were not reported. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 17Apr2021 09:00 (Lot Number: ER8731, at age of 39-year-old) as single dose for covid-19 immunisation. On 09May2021 at 21:00, 36 hours after her injection she developed constant relentless tinnitus in her right ear with accompanying ear pressure. The event resulted in doctor or other healthcare professional office/clinic visit. Treatment included prednisone 40mgs x 6 days, 20mg x1. She now (on May2021) had anxiety, depression, insomnia and was hopeless that this vaccine had ruined her entire life and had been out of work since. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Purified protein derivative (PPD) was given about 6 weeks prior to vaccine (on Mar2021) and unknown results. The patient was not pregnant. The outcome of the events was not recovered.; Sender's Comments: As there is limited information in the case provided, the causal association between the events(Tinnitus, Ear discomfort , Anxiety, Depression, Insomnia) and the suspect vaccine BNT162B2 cannot be excluded. The case will be reassessed once new information is available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
Age: 40.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Acoustic stimulation tests, Deafness, Ear discomfort, Tinnitus
Clinical narrative: Developed sudden hearing loss in right ear.  Along with Tinnitus and fullness with a day or two of the vaccine.
Age: 40.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Acoustic stimulation tests abnormal, Deafness unilateral, Ear discomfort, Sudden hearing loss, Tinnitus
Clinical narrative: Developed sudden hearing loss in right ear.  Along with Tinnitus and fullness with a day or two of the vaccine.
Age: 22.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness postural, Loss of consciousness, Malaise
Clinical narrative: Patient experienced a rash at the injection site. Her mom told  us this after the second dose was already given.
Age: 22.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Injection site rash
Clinical narrative: Patient experienced a rash at the injection site. Her mom told  us this after the second dose was already given.
Age: 49.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blepharospasm, Immediate post-injection reaction, Malaise, Pupil fixed, Syncope
Clinical narrative: Right after vaccination of second dose participants' eyes rolled back of head and she lost consciousness. EMS on site and several nurses right at pt's side. Vitals were taken and an ambulance was called. Pt transported to local emergency department.
Age: 49.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Eye movement disorder, Immediate post-injection reaction, Loss of consciousness
Clinical narrative: Right after vaccination of second dose participants' eyes rolled back of head and she lost consciousness. EMS on site and several nurses right at pt's side. Vitals were taken and an ambulance was called. Pt transported to local emergency department.
Age: 49.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Computerised tomogram, Dyspnoea, Hypotension, Syncope, Tremor
Clinical narrative: Right after vaccination of second dose participants' eyes rolled back of head and she lost consciousness. EMS on site and several nurses right at pt's side. Vitals were taken and an ambulance was called. Pt transported to local emergency department.
Age: 18.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chest X-ray normal, Chest pain, Electrocardiogram repolarisation abnormality, Pericarditis, Troponin
Clinical narrative: 18 yo female presented to ED with midsternal chest and left arm pain 3 days post 2nd dose of Moderna vaccine.  Upon arrival to hospital patient was hemodynamically stable (BP 120/80, HR 70, O2 sats 100% on RA).  Troponins drawn and noted to be uptrending (1.17 then 4.66 after 3 hours).  Patient had mild leukocytosis (12) and EKG showed T-wave inversion at V1 and V2.  CK was normal. Patient treated for myopericarditis and discharged home after 1 day.
Age: 18.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood creatine phosphokinase normal, Chest pain, Electrocardiogram T wave inversion, Electrocardiogram abnormal, Leukocytosis
Clinical narrative: 18 yo female presented to ED with midsternal chest and left arm pain 3 days post 2nd dose of Moderna vaccine.  Upon arrival to hospital patient was hemodynamically stable (BP 120/80, HR 70, O2 sats 100% on RA).  Troponins drawn and noted to be uptrending (1.17 then 4.66 after 3 hours).  Patient had mild leukocytosis (12) and EKG showed T-wave inversion at V1 and V2.  CK was normal. Patient treated for myopericarditis and discharged home after 1 day.
Age: 18.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Myocarditis, Pain in extremity, Troponin increased
Clinical narrative: 18 yo female presented to ED with midsternal chest and left arm pain 3 days post 2nd dose of Moderna vaccine.  Upon arrival to hospital patient was hemodynamically stable (BP 120/80, HR 70, O2 sats 100% on RA).  Troponins drawn and noted to be uptrending (1.17 then 4.66 after 3 hours).  Patient had mild leukocytosis (12) and EKG showed T-wave inversion at V1 and V2.  CK was normal. Patient treated for myopericarditis and discharged home after 1 day.